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Abstract In the recent years, considerable insight has been
gained in to the optimal management of adult asthma. Most
adult patients with asthma have mild intermittent and
persistent disease, and it is acknowledged that many
patients do not reach full control of all symptoms and
signs of asthma. Those with mild persistent asthma are
usually not well controlled without inhaled corticosteroids
(ICS). Studies have provided firm evidence that these
patients can be well controlled when receiving ICS,
especially when disease is of recent onset. This treatment
should be given on a daily basis at a low dose and when
providing a good response should be maintained to prevent
severe exacerbations and disease deterioration. Intermittent
ICS treatment at the time of an exacerbation has also been
suggested as a strategy for mild persistent asthma, but it is
less effective than low-dose regular treatment for most
outcomes. Adding a long-acting beta-agonist (LABA) to
ICS appears to be unnecessary in most of these patients for
optimising control of their asthma. Patients with moderate
persistent asthma can be regarded as those who are not
ideally controlled on low-dose ICS alone. The combination
of an ICS and LABA is preferred in these patients,
irrespective of the brand of medicine, and this combination
is better than doubling or even quadrupling the dose of ICS
to achieve better asthma control and reduce exacerbation
risks. An ICS/LABA combination in a single inhaler
represents a safe, effective and convenient treatment option
for the management of patients with asthma unstable on
inhaled steroids alone. Ideally, once asthma is under full
control, the dose of inhaled steroids should be reduced,
which is possible in many patients. The duration of
treatment before initiating this dose reduction has, however,
not been fully established. One of the combinations
available to treat asthma (budesonide and formoterol) has
also been assessed as both maintenance and rescue therapy
with a further reduction in the risk for a severe exacerba-
tion. Clinical effectiveness in the real world now has to be
established, since this approach likely improves compliance
with regular maintenance therapy.
Keywords Asthma.Beta-2-agonist.
Inhaledcorticosteroids.Hyperresponsiveness
Introduction
Asthma affects 300 million people worldwide (Masoli et al.
2005), with an increasing prevalence in Western Europe
and the USA in particular. International guidelines stipulate
goals for optimising asthma management, such as prevent-
ing chronic and acute symptoms, minimising exacerbations
and emergency care, minimising the use of rescue β2-
agonists and maintaining normal levels of physical activity
(Global Initiative for Asthma 2004). Much has been learned
in the past 25 years with regard to asthma management.
Despite the fact that there is still no cure for asthma, it has
been established in a great number of small and large
studies that many patients can reach a good asthma control
with controller treatment (Global Initiative for Asthma
2004). This can be reached by combining inhaled cortico-
steroids (ICS) and long-acting β2-agonists (LABA), which
is the mainstay of current asthma treatment. The current
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Asthma management with inhaled corticosteroids only
The therapeutic options available for patients with asthma
depend on the severity of the condition (Global Initiative
for Asthma 2004). Generally, asthma is divided into mild
intermittent, mild persistent, moderate persistent and severe
persistent disease, based on respiratory symptoms, noctur-
nal awakening due to symptoms and the severity of airway
obstruction (Table 1; Global Initiative for Asthma 2004).
ICS are the most efficacious therapy currently available
for optimal asthma management, and they are prescribed to
most patients with asthma (see www.ginasthma.org, entered
December 2007). When short-acting beta-2-agonists are
insufficiently reducing symptoms, i.e. to less than once a
day, ICS are advocated as the next step in the management
of newly diagnosed asthma to reach the control of
symptoms and signs of asthma. If this does not occur, then
a LABA is recommended as additional treatment in the
management of asthma. ICS control symptoms, improve
hyperresponsiveness and lung function, reduce the number
of exacerbations and improve health status in most patients
irrespective of the severity of their disease (Barnes 2006).
Both short-term and long-term studies have shown that
inhaled steroids are efficacious in asthma management.
Some effects occur shortly after initiation of the treatment,
while other effects increase with time of treatment. For
instance, ICS improve hyperresponsiveness to a larger
extent with longer duration of treatment (Kerstjens et al.
1992) and preserve the initial lung function improvement
when given for long periods of treatment (Douma et al.
2002; Kerstjens et al. 1992). Long-term studies also suggest
that inhaled steroids reduce the accelerated decline in lung
function, which is now acknowledged to be present in a
subset of asthma patients (Dijkstra et al. 2006; Lange et al.
1998).
Given these assets of inhaled steroids in asthma
management, ICS are the first-line therapy for all patients
who use a β2-adrenoceptor agonist inhaler more than once
a day, and this is reflected in all national and international
guidelines for asthma management (Global Initiative for
Asthma 2004; Lemiere et al. 2004; NHLBI 2002). The
efficacy of ICS is due primarily to the suppression of
virtually every step in the inflammatory cascade that
underlies the airway disease in asthma and the associated
airway hyperresponsiveness that is present in most asthma
patients. Acting via the glucocorticoid receptor, ICS repress
the expression of inflammatory cytokines, their receptors,
adhesion molecules and other disease-inducing mediators.
These effects of ICS and their ability to promote apoptosis
of many cell types including the eosinophil act to reduce
the attraction and activation of inflammatory cells in the
lungs, thereby attenuating inflammation (Barnes 2001).
Furthermore, ICS suppress the pro-inflammatory activity of
airway epithelial and smooth muscle cells, resident cells
with an important pro-inflammatory capacity (Barnes 1996;
Panettieri 2004). Since these cells produce chemokines,
cytokines and pro-fibrotic mediators, they are no longer
innocent bystanders in the inflammatory process and have
become important additional targets for the anti-inflamma-
tory actions of ICS (Barnes 1996).
All types of ICS monotherapy achieve successful control
of persistent asthma in a significant proportion of patients
(Adams and Jones 2006). Several studies have shown that
inhaled steroids are effective in mild intermittent asthma or
newly diagnosed mild asthma. Generally, the dose–re-
sponse curve of ICS is relatively flat for a number of
outcome measures, and for many patients, the therapeutic
benefits of high-dose ICS above low-dose or medium-dose
ICS may be marginal, thus most of the benefit in mild-to-
moderate severity disease is gained in the low-to-moderate
dose range of each drug. Furthermore, many studies have
shown (Adams and Jones 2006; van der Molen et al. 1998)
that for patients who require ICS, starting with a moderate
dose is as effective as starting with a high dose and stepping
down. Individual patients with severe persistent asthma my
gain some benefit from high-dose ICS treatment.
A large, 3-year double-blind study (called START,
Pauwels et al. 1998) assessed whether early intervention
with inhaled ICS (400 μg budesonide) prevented clinical
progression of asthma in newly diagnosed, mild persistent
Table 1 Definition of severity of asthma based on symptoms and lung function
Severity Symptoms Nocturnal awakening FEV1 or PEF
Mild intermittent ≤1/week; when asymptomatic, normal PEF between attacks ≤2/month >80% predicted
Mild persistent >1/week, but <1/day >2/month >80% predicted
Moderate persistent Daily >1/week 60–80% predicted
Severe persistent Daily; limited physical activity Frequent ≤60% predicted
FEV1 Forced expiratory volume in 1 s, PEF peak expiratory flow
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predicted and an average of 4 days with symptoms per
week). These patients were newly diagnosed with asthma
and had never been treated with inhaled steroids previously.
The primary outcomes were the time to first very severe
exacerbation (hospital visit or admission) and decline in
post-bronchodilator FEV1. During the first year, approxi-
mately 34% of the patients treated with placebo needed
ICS, and 4% had a severe exacerbation, compared with
20% that needed additional treatment and 2% with a severe
exacerbation in the budesonide treated individuals (Fig. 1;
Pauwels et al. 2003).
Differences were maintained until the end of the 3-year
follow-up (50% and 6% with placebo versus 30% and 3%
with ICS, respectively; Pauwels et al. 2003). Decline in
post-bronchodilator FEV1 was significantly larger in the
placebo arm, though differences were small during this 3-
year follow-up. Thus, early intervention with low-dose ICS
prevented clinical progression of asthma.
Finally, one study assessed whether intermittent short-
course ICS treatment, guided by a symptom-based action
plan, alone or in addition to daily treatment with budeso-
nide was more effective during 1-year treatment (Boushey
et al. 2005). A third arm used the anti-leukotriene
zafirlukast. The authors concluded that patients with mild
persistent asthma, who were of similar severity as the
START study (Pauwels et al. 2003), could be treated with
intermittent courses of inhaled or oral corticosteroids in
conjunction with an action plan. Indeed, the number of
patients with a severe asthma exacerbation did not differ
between the groups. However, numbers were low and lower
than in previous studies, and follow-up was only 1-year,
making it difficult to find a potential effect of either drug
regimen on severe asthma exacerbation rates (total number
of patients included 225). Thus, a likely better conclusion
of this study is that regular inhaled steroid use is preferable,
since regular use of inhaled budesonide was significantly
better than intermittent use in improvement of pre-bron-
chodilator FEV1, asthma control scores, number of symp-
tom-free days, airway hyperresponsiveness and markers of
airway inflammation.
Prediction of beneficial response to inhaled steroids
alone
It is interesting to note that some studies have investigated
which factors contribute to the efficacy of instituting ICS in
asthma. The most consistent beneficial factors for improve-
ment in lung function or hyperresponsiveness are a shorter
duration of asthma before treatment (Fujimoto et al. 2006),
non-smoking (Fujimoto et al. 2006; Kerstjens et al. 1993;
Kerstjens et al. 1995; Pedersen et al. 2007), male gender
(Green et al. 2002a), better reversibility of airway obstruc-
tion (Kerstjens et al. 1993; Martin et al. 2007), sputum
eosinophilia (Fujimoto et al. 2006), and higher serum IgE
levels (Kerstjens et al. 1993). One study showed that short-
term responders (i.e. increase of greater than 5% in FEV1 in
6 weeks) had also a long-term response when ICS were
continued, supporting that lung function improvement when
monitored should trigger physicians to encourage their
patientstocontinue using inhaledsteroid (Martin etal.2007).
Asthma management with long-acting β-agonists alone?
Inhaled β2-agonists are powerful agents used to relieve the
bronchoconstriction associated with asthma. By far, the
most important action is stimulating the β2-receptors
located in airway smooth muscle resulting in smooth
muscle relaxation (Nelson 2006). This article will only
deal with LABA. LABA provide longer symptom control,
which is a particularly useful feature for preventing night-
time symptoms. There are two main LABA, i.e. salmeterol
and formoterol. Salmeterol is highly lipophilic and diffuses
through the lipid bi-layer in muscle cell membranes to
reach the β2-receptors, explaining the slower onset and
long duration of action (Nelson 2006). Formoterol, being
less lipophilic, has a faster onset of action, similar to short-
acting β2-agonists, and is believed to be incorporated into
the lipid bi-layer to serve as a reservoir, accounting for its
prolonged action (Nelson 2006).
Frequent use of short-acting β-agonists or LABA
generally indicates a significant inflammatory process that
should be controlled with anti-inflammatory drugs such as
ICS. The role of LABA in the management of asthma has
previously been debated. The role of LABA monotherapy
was specifically addressed in a study called Salmeterol Off
CorticoSteroids (Lazarus et al. 2001). Subjects with mild
Fig. 1 Proportion of events in mild asthma patients who were steroid
naïve and treated with inhaled steroids (Pauwels et al. 2003)
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olone acetonide (TAA) 400 μg twice daily for 6 weeks. The
164 patients whose asthma became well controlled were
then randomised for 16 weeks to continue on TAA, to
receive instead the LABA salmeterol (42 μg bi-daily [b.i.d.])
orplacebo.Whileasthmacontroldeteriorated inthoseplaced
on placebo, there was no difference between those continu-
ing on ICS and those receiving LABA monotherapy for
conventional clinical outcomes such as morning and evening
peak expiratory flow (PEF), symptom scores, rescue
albuterol use or quality of life. Patients who continued on
salmeterol had, however, a similar rate of treatment failures
and asthma exacerbations compared to those switched to
placebo and a significantly higher rate than patients with
ongoing steroid use. Furthermore, a difference in markers of
airway inflammation developed, i.e. stable inflammatory
m a r k e r si np a t i e n t su s i n gI C S ,w h e r e a si nt h o s eo n
salmeterol alone, there was deterioration in sputum eosino-
phils, eosinophil cationic protein, exhaled nitric oxide and
methacholine sensitivity, similar to the changes seen in the
placebo group. The fundamental message from this study
was “The findings indicate that salmeterol should not be
used as monotherapy for treatment of persistent asthma...”
(Lazarus et al. 2001).
At present, the use of LABA as monotherapy clearly
appears to be less effective than ICS alone (Lazarus et al.
2001; Nelson et al. 2006) and has been associated with
increased asthma deaths in two post-marketing surveillance
studies in the USA and UK (Castle et al. 1993; Nelson et al.
2006). An increased risk of respiratory-related mortality or
life-threatening events occurred with salmeterol compared
with placebo in a population of patients with asthma
(Nelson et al. 2006), and these differences were significant
for the African-American subset of study participants. The
findings were in accordance with a study undertaken in the
UK (Castle et al. 1993) in which numerically higher
(though not significantly) numbers of asthma-related deaths
were recorded with regular use of salmeterol. The popula-
tion in the US surveillance study had, in general, very
poorly controlled asthma, yet less than 50% of these
patients reported being treated with ICS. The African-
American population had even less well-controlled asthma,
with lower lung function and an even lower proportion of
patients prescribed ICS. In a meta-analysis of the LABA
data, Salpeter et al. (2006) performed a search of databases
up to the end of 2005 to assess the risk for severe, life-
threatening or fatal asthma exacerbations associated with
the use of LABA. They limited their search to placebo-
controlled trials that lasted at least 3 months. The results
reported for fatal and near-fatal asthma attacks largely
repeated the previously published data of increased numb-
ers of near-fatal asthma with LABA treatment from the
Symbicort as Maintenance And Reliever Therapy
(SMART) study (Nelson et al. 2006). In the discussion,
the authors suggest that the LABA use may be responsible
for the increased asthma mortality since 1960. However, as
Nelson pointed out (see comments in review), asthma
mortality was steadily declining in the USA since the
introduction of LABA, and most studies analyzed did not
require concomitant use of inhaled steroids. In a recent
overview of the safety of LABA in asthma, two new more
extensive meta-analyses (20,592 subjects and 6,988 sub-
jects, as yet only available in abstract form (Oppenheimer
and Nelson 2008), were discussed that showed a significant
reduction in exacerbations when ICS was used in combi-
nation with LABA, as well as the risk for hospitalisation.
The data to date available suggest that a small sub-class of
asthmatics may be prone to deleterious effects of LABA.
However, from the data available, it cannot be ascertained
whether this is some rare susceptibility to a deleterious effect
of LABA or that this is the consequence of monotherapy with
LABA that controls the symptoms but may mask increasing
inflammation in patients who lack adequate access to medical
care. Therefore, all national and international asthma consen-
sus statements recommend the use of LABA only in
combination with ICS (Masoli et al. 2005; Global Initiative
for Asthma 2004). The Medicines and Healthcare Products
Regulatory Agency Safety Update on LABA in the UK
has also recently concluded that at present, the benefits of
LABA outweigh the risk, and it is important that patients
take their asthma medicine as prescribed, and this should
be in conjunction with ICS (http://www.mhr.gov.uk/
Safetyinformation/Generalsafetyinformationandadvice/
Productspecificinformationandadvice/Asthma/index.htm).
Clinical evidence suggesting an anti-inflammatory
action of LABA when added to ICS
The first clinical suggestion that LABA might be more than
just a bronchodilator when they are added to an ICS came
with the Formoterol And Corticosteroids Establishing
Therapy (FACET) landmark study (Pauwels et al. 1998).
Eight-hundred and fifty-two patients with asthma were first
treated for 4 weeks with 800 μg of budesonide twice daily.
They were then randomised to either budesonide 100 or
400 μg twice daily, and half in each group received
additional formoterol 12 μg twice daily for 1 year. As
anticipated, all the conventional measures of asthma
control, pulmonary function, symptoms and rescue albu-
terol use were improved by the addition of formoterol to
either dose of budesonide. What was not anticipated was
that the addition of formoterol to either dose of budesonide
reduced the occurrence of asthma exacerbations—both
minor exacerbations and those requiring prednisone treat-
ment. A meta-analysis examining the addition of salmeterol
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of ICS confirmed the findings of FACET; that is, the
addition of a LABA produces a greater reduction in
exacerbations than the higher dose of ICS (Shrewsbury et
al. 2000). Exacerbations of asthma are considered to reflect
ongoing airway inflammation, and hence a reduction in the
exacerbation rate with a drug is considered (indirect)
evidence of its anti-inflammatory activity. Direct clinical
evidence for some anti-inflammatory activity of LABA
when added to ICS has also been sought. In three studies,
there was a significant anti-inflammatory effect (e.g. a
reduction in numbers of eosinophils and mast cells) seen
with the combination of an inhaled steroid and salmeterol,
which was not seen with the same dose of inhaled steroid
alone, or in two cases with a considerably higher dose of
inhaled steroid alone (Koopmans et al. 2006; Li et al. 1999;
Wallin et al. 2003). In mild disease (Kips et al. 2000), the
addition of formoterol to budesonide showed comparable
effects on sputum eosinophils as the treatment with a higher
dose of ICS. A more recent study, however, found a more
pronounced reduction in sputum inflammatory cells with a
high-dose budesonide than with the addition of formoterol
to a low dose of inhaled budesonide (Green et al. 2006).
Combination of LABA and ICS in daily treatment:
the first studies
Greening et al (1994) conducted the first double-blind,
parallel group trial of 6-month duration in 426 asthmatic
subjects who were symptomatic despite maintenance
therapy with the ICS, beclomethasone dipropionate (BDP;
200 μg b.i.d.). Subjects were randomised to receive
salmeterol xinafoate (50 μg b.i.d.) and BDP (200 μg b.i.d.)
delivered via separate inhaler devices or BDP alone at a
higher dose of 500 μg b.i.d. Both treatment interventions
significantly improved mean morning PEF, but the LABA/
ICS combination therapy was superior at all time points.
Other end points that favoured salmeterol/BDP over high-
dose BDP alone included diurnal variation in PEF, daytime
and night-time symptoms and rescue bronchodilator use.
There was no significant difference in the exacerbation rate
between the two treatment groups indicating that salmeterol,
given chronically with BDP, was notassociated with any risk
of asthma deterioration over the duration of the study.
However, there was no protective effect in this study on
exacerbation rates. Except for exacerbation rates and
morning PEF, the addition of salmeterol to a standard dose
of BDP was more effective clinically than increasing, by 2.5-
fold, the dose of BDP (Greening et al. 1994).
The clinical significance of these finding was endorsed
further when the landmark FACET study established that
combination therapy was also clinically superior to gluco-
corticoid alone when exacerbation rate was used as the
primary outcome measure (Pauwels et al. 1998). Indeed, the
exacerbation rate in subjects with moderately severe asthma
was lower when the LABA, formoterol (9 μg b.i.d.), was
added to low and high doses of another glucocorticoid,
budesonide (that is 100 or 400 μg b.i.d.), when compared to
the ICS alone (Pauwels et al. 1998). This study also showed
that a fourfold boost of ICS improved all outcomes, apart
from severe exacerbations. Other studies have subsequently
shown that a twofold rise in the dose of ICS was not
effective in asthma management for most outcomes
assessed, including the reduction in the rate of asthma
exacerbations or the prevention of exacerbations (O’Byrne
and Parameswaran 2006).
Confirmation of effects: superiority of LABA/ICS
combination therapy as a class effect
Since the seminal report of Greening et al. (1994), many
trials have been conducted comparing the clinical effec-
tiveness in asthma of LABA/ICS combination therapies in
separate inhaler devices with a higher dose of an ICS alone.
Most studies concerned mild to moderate severe asthma,
and predominantly moderately severe asthma patients were
included in these studies. What has emerged, unambigu-
ously, is that the clinical superiority of salmeterol and BDP
in combination over higher-dose ICS alone is unequivocal
and class specific (that is, it is not limited to salmeterol or
BDP but a generic effect of LABA and ICS when used in
combination). Indeed, meta-analyses of nine parallel group
trials in which the clinical efficacy and safety of salmeterol
in combination with either BDP or fluticasone were
assessed and compared to a higher dose of ICS given as a
monotherapy led Shrewsbury et al. (2000) to conclude that
“....giving salmeterol to patients who have symptoms on at
least 400 μg BDP per day will result in better lung function,
better control of symptoms, less need for rescue medica-
tion, and fewer exacerbations than increased doses of
inhaled steroid.”
The results of the more recent Gaining Optimal Asthma
controL (GOAL) study has also confirmed the superiority
of salmeterol/fluticasone in combination yet within one
inhaler device in achieving greater asthma control than the
ICS alone (Bateman et al. 2004). This study in predomi-
nantly moderate to severe persistent asthma (10% with mild
disease) assessed how frequently ideal asthma control can
be achieved. Three groups were included: steroid-naive,
low-dose, and moderate-dose ICS use at study entry, and all
groups were not well controlled. The study population was
randomly allocated to either increasing doses of ICS alone
or similar doses together with the LABA salmeterol for
1 year. Phase I of the study was dose escalation, whereby
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achieved or until the maximum dose was reached (flutica-
sone 1000 μg, or fluticasone 1000 μg and salmeterol
100 μg daily). Phase II was the time after total control was
achieved or after 12 weeks on the maximum dose of drug.
Table 2 shows the definition of total control and well
controlled in the GOAL study, compared to the Global
Initiative For Asthma guidelines.
Total asthma control, defined as no symptoms, normal
lung function and no limitation of activities, was achieved
in less than 50% of the overall population and less than
30% of those already taking moderate doses of ICS at
randomisation, even with the highest doses of combination
treatment. Well-controlled asthma, defined as mild occa-
sional symptoms (as per Table 2), was achieved in up to
78% of patients not receiving ICS before study entry and in
62% of those already on moderate doses of ICS (Fig. 2;
Bateman et al. 2004). The combination of ICS and LABA
was always significantly better than ICS alone. Moreover,
control was reached more rapidly and at a lower ICS dose
with the combination treatment. A further analysis
(Woodcock et al. 2007) investigated whether the GOAL
study would show similar results when single specific
endpoints, as used in the guidelines (Global Initiative for
Asthma 2004), were investigated. It showed that salmeterol/
fluticasone treatment resulted in an additional 66 symptom-
free days per year compared with fluticasone alone, and in
all strata, symptom-free days and rescue-free days were
more probable in patients receiving combination therapy
(Woodcock et al. 2007). Again, the outcome was better
after 52 weeks of treatment (during the time that patients
remained on the dose at which they had achieved total
control or the maximum study dose) than with 12 weeks,
which is in line with the GOAL study. Moreover, it fits with
previous studies that long-term treatment is needed with
ICS to reach maximal reduction in airway inflammation
and hyperresponsiveness (Douma et al. 2002; Dijkstra et al.
2006; Kerstjens et al. 1992; Lange et al. 1998). The GOAL
study shows that recommendations by guidelines (Global
Initiative for Asthma 2004) to assess patients according to
their level of control and then treat them with stable dosing,
followed by stepping up of treatment to achieve and
maintain asthma control, is effective. However, the danger
of over-treatment is not imaginary in this way when the
highest dose is maintained, and asthma guidelines recom-
mend that once asthma control has been achieved and
maintained for 3–6 months, treatment should be reviewed
and dose reduction attempted, with careful monitoring to
Table 2 International goals of asthma treatment and definition of total and well control
GINA goals GOAL total control
a, all of below criteria GOAL well controlled
a, ≥2 of below criteria
Daytime symptoms Minimal/none None ≤2 days for short time of day
SABA rescue needed Minimal/none None ≤2 days and ≤4 times /week
Morning PEF Near normal ≥80% predicted ≥80% predicted
Nocturnal awakening Minimal/none None None
Emergency visits None None None
Side effects Minimal None needing treatment changes None needing treatment changes
SABA Short-acting β-agonist, PEF peak expiratory flow
aDuring at least 7 out of 8 weeks
Fig. 2 Well control and total
control with fluticasone and flu-
ticasone/salmeterol in the
GOAL study (Bateman et al.
2004). WC Well controlled, TC
total control, FP fluticasone
propionate, Salm salmeterol, S
severity level
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of the GOAL study; thus, treatment reduction did not take
place. In a subsequent study, Bateman et al. (2006) studied
stepping-down treatment in a 12-week study comparing
patients who were well controlled on salmeterol/fluticasone
(50/250 μg b.i.d.) for at least 4 weeks and who were then
switched to either salmeterol/fluticasone 50/100 μg b.i.d. or
fluticasone 250 μg b.i.d for 12 weeks. It was shown that
stepping down to the combination was more effective than
to fluticasone alone, with respect to PEF, symptom control
and rescue albuterol use. However, still not all patients were
well controlled during the stepping down of treatment; that
is, 23% and 31% were not controlled when stepping down
to the combination and fluticasone-alone groups, respec-
tively. Thus, future studies have to elucidate which patients
can step down safely and after which period of treatment.
This is important, also in the light of the GOAL findings
that with sustained treatment, more patient will achieve
higher levels of control and that the achievement of control
is a function of both dose and duration of treatment
(Bateman et al. 2004; Bateman et al. 2006).
The clinical superiority of LABA/ICS combination ther-
apies also extends to subjects with moderate persistent
asthma treated with budesonide combined with formoterol.
This was shown in the FACET study. Furthermore, the
Oxis and Pulmicort Turbuhaler In the Management of
Asthma (OPTIMA) study convincingly demonstrated that
adding formoterol (4.5 μg b.i.d.) to low-dose budesonide
(200 μ b.i.d.) for 1 year in subjects with moderate severe
asthma was more effective than doubling the dose of ICS
in increasing the time to first severe asthma exacerbation
(O’Byrne et al. 2001).
Of importance, a recent meta-analysis suggested that the
beneficial effects of the addition of LABA to ICS depend
on the outcome measures under study (Gibson et al. 2007).
For instance, in steroid-naïve patients, the number of severe
exacerbations was not significantly different with the
addition of LABA to ICS versus ICS alone, but the
outcome measured as the improvement in PEF, reduction
in rescue beta-agonist use and percent of symptom-free
days did improve significantly. The greatest benefit
occurred when the addition of LABA to ICS was
compared with continuing ICS alone in a similar dose;
that is, in that way, the number needed to treat for the
prevention of a severe exacerbation is 18 (Table 3; Gibson
et al. 2007). Finally, a composite score of asthma control
(see above for definition) was always better with LABA/
ICS treatment when comparing with a similar dose in
steroid-naïve patients, in patients using a similar dose of
ICS and in patients with a higher ICS dose (Gibson et al.
2007).
This was also found in a further analysis of the GOAL
study comparing the above composite score of control and
the separate items of this score (Bateman et al. 2007). The
composite score of control took, as expected, always longer
to be reached than the individual items. Night-time
awakening responded most rapidly, and daytime symptoms
took longest to respond. Again, the response was always
better with LABA/ICS treatment than ICS treatment alone
yet with one exception. Night-time awakening had a more
rapid response following treatment with fluticasone alone, a
finding that was unexpected and not easy to explain given
the fact that salmeterol provides bronchodilation for a
period that covers the nigh-time setting. Moreover, both
treatments contained an ICS, which reduces persistent
airway inflammation that is similarly present at day and
night in patients with nocturnal awakenings (ten Hacken et
al. 1998). Notwithstanding the more rapid control of night-
time awakening with fluticasone, LABA/ICS combination
provided again a better control at the end of 12 weeks
(Table 4; Nelson et al. 2000). An important message of the
study is that using any of the individual criteria of control in
isolation will over-estimate a patient’s level of overall
control (Table 4; Nelson et al. 2000). Moreover, to establish
full control, a longer duration of treatment is necessary,
supporting the conclusion of the initial GOAL study
(Bateman et al. 2006).
No confirmation of superiority of LABA/ICS
combination therapy in mild disease
Patients with mild persistent asthma form a sizable
proportion of people with asthma (up to 70%; O’Byrne
and Parameswaran 2006). Nevertheless, they are frequently
unknown to their physician since they rarely visit their
family doctor with symptoms of the disease and are seldom
seen in a secondary or tertiary healthcare setting.
Few studies have allowed assessing whether treatment
approaches with combined LABA/ICS are effective above
ICS alone in mild persistent asthma. O’Byrne recently
summarised these studies (O’Byrne and Parameswaran
2006). The OPTIMA study is one of them and allowed to
study mild persistent asthma separately from moderate
Table 3 Comparison of LABA+ICS with ICS alone, a meta-analysis
(Gibson et al. 2007)
ICS regimen Number Severe
exacerbations
Asthma
control
Similar dose 4,312 Superior,
NNT=18
Superior
Similar dose
in ICS naïve
968 NS Superior
Higher dose 4,951 NS Superior
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asthma group consisted of almost 700 individuals who had
never used ICS. In this group, budesonide alone (200 μg/
day) was compared with the same dose of budesonide plus
formoterol or budesonide plus placebo for 1 year of
treatment. The primary outcome was rate of severe asthma
exacerbations; this rate was 0.77 per patient per year in the
placebo-treated group, falling to 0.29 per patient per year
with low-dose budesonide alone. All other study outcomes,
including days with asthma symptoms and nights with
nocturnal symptoms, were also improved by budesonide
treatment. The combination of budesonide and formoterol
did not provide any additional benefit when compared with
budesonide alone. Thus, for patients with mild persistent
asthma, low-dose ICS alone are the preferred treatment
option. By contrast and confirming earlier studies, patients
with moderate persistent asthma who used ICS at study
entry did show a striking and significant difference in
asthma exacerbations when formoterol was added to
budesonide (Fig. 3; Pauwels et al. 1998,O ’Byrne et al.
2001). The findings suggest that combination treatment is
not appropriate for all patients with persistent asthma and
that benefit is only seen in those not ideally controlled on
low doses of ICS alone.
Delivery of LABA/ICS combination therapies
by a single-inhaler device
Following confirmation of the efficacy and safety of LABA
and ICS administered in combination by separate-inhaler
devices, a number of studies were performed comparing the
efficacy and safety of salmeterol/fluticasone (Seretide/
Advair; GlaxoSmithKline, Stevenage, UK) and formo-
terol/budesonide (Symbicort; AstraZeneca, Lund, Sweden)
delivered by single-inhaler devices (Miller-Larsson and
Selroos 2006). The combination of two complementary
treatments in one inhaler has the advantage that it simplifies
the management of asthma patients. Although differences
in the effectiveness of the combination therapies between
the different methods of administration were reported in
some studies, the balance of evidence demonstrates similar
efficacy and safety profiles irrespective of whether the
components of the combination were delivered in single or
separate inhalers (FitzGerald et al. 2003; Ind et al. 2004;
Nelson et al. 2003; Price et al. 2007; Zetterström et al.
2001, Pohl et al. 2006, Lundborg et al. 2006).
Formoterol/budesonide as a maintenance and rescue
therapy—a Symbicort SMART approach to asthma
management
Despite aggressive fixed-dose combination therapy with
ICS and LABA, a proportion of patients with asthma
remains sub-optimally controlled, based on the need for
rescue therapy and rates of severe exacerbations. Therefore,
studies were set up to assess whether the regular use of the
combination of budesonide and formoterol in one inhaler
(so-called maintenance treatment) could also be used as
rescue therapy (O’Byrne et al. 2005; Rabe et al. 2006a;
Scicchitano et al. 2004). This approach is possible because
formoterol is an inhaled β2-agonist that has a rapid onset
and a long duration of action and can thus be used as a
rescue therapy instead of a separate short-acting β2-agonist
(Ringdal et al. 2003). Moreover, it has a significant dose-
dependent increase in lung function with increasing doses
of 6, 12, 24 and 46 μg (Ringdal et al. 1998). The strategy of
combined maintenance and rescue treatment was compared
in one study (O’Byrne et al. 2005) with a fourfold higher
dose of ICS as maintenance and a short-acting β2 agonist
Table 4 Proportion of patients with control after 12-week treatment in the GOAL study (Nelson et al. 2000)
No night-time
awakening (%)
PEF ≥80%
predicted (%)
No rescue
use (%)
No daytime
symptoms (%)
Total
control (%)
Fluticasone 68 47 36 25 14
Salmeterol/fluticasone 75 57 48 35 23
Fig. 3 Comparison of dose–response in ICS and the addition of
LABA to ICS in two studies with mild asthma and moderate severe
asthma (Pauwels et al. 1998;O ’Byrne et al. 2001). B Budesonide, For
formoterol
210 Naunyn-Schmiedeberg’s Arch Pharmacol (2008) 378:203–215as rescue during 1-year follow-up. Patients enrolled were
adults and children with moderate to severe asthma.
Findings of this study show that the use of this combination
as both maintenance and rescue greatly reduces risk for
severe asthma exacerbations when compared with other
approaches (Fig. 4), with an associated reduction in oral
corticosteroid use.
This is of importance, since the FACET study (Pauwels
et al. 1998) showed that the only benefit of a fourfold
increase in inhaled steroid dose, used as a maintenance
treatment, was the reduction in severe exacerbations. This
study (O’Byrne et al. 2005) thus shows that a similar
benefit can be reached when using a lower cumulative dose
of inhaled steroids, yet using the formoterol/budesonide
inhaler as a maintenance and rescue treatment. An
unexpected finding was that this so-called SMART ap-
proach was that it did not only markedly reduce the number
of severe exacerbations requiring medical attention (the
primary outcome measure) throughout the 1-year treatment
period. It is interesting to note that it also reduced the need
for oral corticosteroids and improved symptom control
including nocturnal awakenings and lung function com-
pared with terbutaline for relief and either budesonide/
formoterol or a fourfold higher dose of budesonide for
maintenance therapy. A concern about this approach is that
some patients might end up using the combination inhaler
frequently and receive an unacceptably high dose of ICS.
However, this was not the case, as the mean number of
additional doses of combination inhaler was only one dose
per day and very few patients required high doses.
A further study compared this approach with formoterol/
budesonide- versus budesonide-adjustable dosing twice
daily (Rabe et al. 2006a). Again, both treatments proved
effective, and there were few treatment failures in either
group. The majority received extra reliever medication on
only 0.7% of the study days, and this was better with the
LABA/ICS treatment; that is, 50% of the patients used only
1-day reliever treatment for 5 months, whereas this was
6 days in the budesonide-adjustable maintenance dosing
group. Furthermore, the adjustable dosing provided better
health-related quality of life and better patient satisfaction,
despite a lower average daily ICS dose, i.e. 448 versus
1,152 μg/day in the budesonide group.
Thus, for some patients who need a maintenance
treatment with a combination inhaler containing budesonide
and formoterol, the inhaler can also be used as rescue when
needed, thereby allowing patients to manage their asthma
with one inhaler. One study showed that the budesonide
component was needed to obtain the beneficial role (Rabe
et al. 2006b), since the formoterol/budesonide rescue
treatment reduced the number of severe exacerbations by
33% over formoterol as needed, both in addition to the
maintenance treatment with formoterol/budesonide. This
was, however, not due to a higher dose of budesonide used,
since there was only a very modest increase in the ICS dose
for the formoterol/budesonide SMART approach. It likely
happened because of the early administration of the ICS,
given as part of the rescue treatment at the time of
worsening asthma control. Apparently, asthmatic patients
are able to detect worsening of asthma quite early. This is in
line with the findings in the FACETstudy (Tattersfield et al.
1999), showing that exacerbations are not explosive events,
as previously believed, but evolve slowly over several days
until the clinical worsening prompts the introduction of oral
corticosteroids with/without antibiotics. Of importance is
that the patients were able to reach this level of asthma
control without any help of their physician but managed
independently to adjust their treatment to the rapid
variability of their disease. Finally, this novel treatment
approach reduced both ICS and oral corticosteroid expo-
Fig. 4 Outcome of SMART
treatment versus fixed dose
budesonide/formoterol or bude-
sonide. PEF Peak expiratory
flow, ER emergency room
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cortisol and adrenal function, compared with budesonide
800 μg/day (O’Byrne et al. 2005; Scicchitano et al. 2004).
The above studies pertain to moderate to severe asthma
patients not well controlled on ICS alone. Only when
patients were poorly controlled on low-dose or high-dose
ICS and LABA therapy were they randomised in the above
studies, and the authors gave the message that the results
“should not be extrapolated to patients with intermittent
asthma, however, or to those well controlled on ICS alone”
(Rabe et al. 2006b). These patients can do well on the
treatment they have at that time.
Prediction of beneficial response to LABA+ICS
as initial maintenance therapy
It has been clearly shown that adding a LABA to ICS is
more beneficial than increasing the dose of ICS with
respect to clinical symptom relief in patients with all but
mild asthma. However, not all patients respond equally
well. Ernst et al. (2008) therefore investigated which
patients might respond better to initial therapy with the
combination or with ICS alone. Data from five randomised
clinical trials were pooled to investigate this. Overall, the
trials in moderate to severe asthma patients (daily symp-
toms in 71%, greater than or equal to two nights awakening
per week in 42%) showed that patients were 1.8 times more
likely to achieve well-controlled asthma within 12 weeks
with combination therapy than with fluticasone alone. The
benefit increased in subjects reporting a duration of asthma
of 10 years or more to a level of 2.2 times. None of the
other factors assessed, i.e. symptom frequency or severity,
rescue beta-agonist use, severity of lung function impair-
ment or degree of reversibility, was able to distinguish
patients who would benefit more than average from the
combination LABA/ICS treatment compared with the ICS
treatment alone. The study did not assess the number of
exacerbations, for which the follow-up time of 12 weeks
was too short. Thus, this does not exclude that inhaled
steroids may still be preferred in mild persistent disease, a
group of subjects that was not specifically investigated in
this meta-analysis, as was the case in the OPTIMA study
(O’Byrne et al. 2001).
Furthermore, it would be of interest to know whether
those individuals with longstanding asthma have a more
neutrophilic or mast cell type of asthma, for which LABA
might have additional benefits (Maneechotesuwan et al.
2005; Reid et al. 2003), and inhaled steroids do work less
effectively (Green et al. 2002a). Thus, future studies have to
investigate whether sputum measures of inflammation may
better help to distinguish which patients need combined
treatment, especially since a treatment with ICS aiming at
the control of sputum eosinophilia and symptoms was
better at improving asthma control than the usual care
according to symptomatic treatment (Green et al. 2002b),
though it is fair to mention that this was not tested with the
combination of formoterol/budesonide as the SMART
approach but with ICS and additional increase or reduction
in ICS or LABA treatment. This might have a benefit since
the same authors have shown that patients with asthma and
sputum eosinophilia respond better to low-dose inhaled ICS
in hyperresponsiveness and quality of life than non-
eosinophilic asthma (Berry et al. 2007).
Formoterol/budesonide SMART
and salmeterol/fluticasone maintenance
There have been only four double-blind studies (Bousquet
et al. 2007; FitzGerald et al. 2005; Kuna et al. 2007; Price
et al. 2007) and some open studies (Aalbers et al. 2004;
Vogelmeier et al. 2005) that formally have compared the
SMART approach with formoterol/budesonide with the
maintenance approach with salmeterol/fluticasone.
However, they are difficult to judge, since some studies
did not adjust dosing according to symptoms as needed by
the patient but were driven by an approach based on the
GOAL study (FitzGerald et al. 2005; Price et al. 2007).
Thus step-up and step-down management was performed
based on a composite score. As shown above in this
overview, this may have effects on the outcome of the
study. One study had a different dose of inhaled steroid
used, i.e. 200 budesonide and 6 μg formoterol bid and
additional doses for adjustable maintenance dosing and
500 μg fluticasone and 25 μg salmeterol for maintenance
dosing (Bousquet et al. 2007). In that study, treatment with
the SMART approach had a better outcome for number of
exacerbations, without a difference in lung function, with a
mean lower dose of ICS used in the budesonide/formoterol
arm (792 versus 1,000 μg/day). However, it may well be
that the patient in the salmeterol/fluticasone group would
have needed less ICS. Thus, one cannot simply compare
these regimens with each other.
The other study (Kuna et al. 2007) compared the 200/6-
(SMART approach) with the 400/18-μg b.i.d. (fixed)
treatment of budesonide/formoterol and with 125/25 μg
fluticasone/salmeterol b.i.d. All treatments provided similar
marked improvements in lung function, asthma-controlled
days and quality of life. Budesonide/formoterol as the
SMART approach reduced asthma exacerbation rates and
maintained similar daily asthma control yet at a lower
overall drug load compared with the fixed-dose salmeterol/
fluticasone and budesonide formoterol. This suggests that
indeed adjustable dosing in addition to maintenance
treatment is favourable.
212 Naunyn-Schmiedeberg’s Arch Pharmacol (2008) 378:203–215We have to await a study investigating the optimisation of
treatment and reduction with salmeterol/fluticasone in com-
parison to the SMARTapproach with formoterol/budesonide
to draw a definite conclusion. For the time being, one should
just realise that both treatments are optional and have to be
adjusted to the patients need, as long as no exacerbations
occur and good control of asthma is present.
Conclusions
In the recent years, considerable insight has been gained in
to the optimal management of adult asthma. Most patients
with asthma have mild intermittent and persistent disease.
Those with mild persistent asthma are usually not well
controlled without ICS. Studies have provided firm evi-
dence that these patients can be well controlled when
receiving ICS, especially when disease is of recent onset.
This treatment should be given on a daily basis at a low
dose and when providing a good response should be
maintained to prevent severe exacerbations and disease
deterioration. Intermittent ICS treatment at the time of an
exacerbation has also been suggested as a strategy for mild
persistent asthma, but it is less effective than low-dose
regular treatment for most outcomes. Adding a LABA to
ICS appears to be unnecessary in most of these patients for
optimising control of their asthma.
Patients with moderate persistent asthma can be regarded
as those who are not ideally controlled on low-dose ICS.
The combination of an ICS and LABA is preferred in these
patients, irrespective of the brand of medicine, and this
combination is better than doubling the dose of ICS to
achieve better asthma control and reduce exacerbation risks.
One of the combinations available to treat asthma (budeso-
nide and formoterol) has also been assessed as both
maintenance and rescue therapy with a further reduction
in the risk for a severe exacerbation. Clinical effectiveness
in the real world now has to be established, since this
approach likely improves compliance with regular mainte-
nance therapy.
Other strategies that have been shown successful are the
monitoring of eosinophils in the sputum and the level of
hyperresponsiveness, but these options are beyond the
scope of this article, as are the treatment with leukotriene
antagonists (though less effective than LABA/ICS) and
other immuno-modulating agents. It goes without saying
that pharmacotherapy should always be accompanied by
advice of smoking cessation given the negative effects on
response to inhaled steroids, next to other negative health
effects. Furthermore, education about the disease and use of
inhalers and allergen avoidance and a written management
plan are part of an optimal treatment strategy for asthma
patients.
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